The U.K. is under pressure to offer a better deal to global pharmaceutical firms, as a slew of pulled investments and stalled drug pricing talks loom over U.S. President Donald Trump’s state visit to Britain. Drug companies have been urging U.K. authorities to pay more for drugs and improve the competitive landscape ahead of a…
London’s FTSE 100 touched a fresh record high on Friday – and some market watchers see more upside ahead for the long-maligned index, with U.S. tariffs, macroeconomic influences and outperformance in certain sectors sparking a widespread reassessment of U.K. equities. The U.K. index — home to some of the world’s most renowned companies, including AstraZeneca…
AstraZeneca CEO Pascal Soriot, pictured in London on June 28, 2023, reportedly wants to move the company’s stock listing from London to the United States. Justin Tallis | Afp | Getty Images Pressure is piling on London’s stock exchange, with reports that British pharma giant AstraZeneca may move its listing to the U.S. delivering yet…
Traders work on the floor of the New York Stock Exchange on Feb. 4, 2025. NYSE U.S. stock futures were little changed Wednesday night after the major averages posted back-to-back winning sessions. Futures tied to the Dow Jones Industrial Average were marginally higher. S&P 500 futures and Nasdaq 100 futures were both trading around flat….
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Market rotation: The Dow was the big winner Monday, tracking for its first close above 44,000. However, the pressure on the S & P 500 and…
President Donald Trump looks on as his nominee for the chairman of the Federal Reserve Jerome Powell takes to the podium during a press event in the Rose Garden at the White House, November 2, 2017 in Washington, DC. Drew Angerer | Getty Images Talk about an eventful week. Normally, when the Fed cuts interest…
(Bloomberg) — AstraZeneca Plc shares plunged in London, erasing about £14 billion ($18 billion) of market value, amid escalating concerns over a Chinese probe into the UK drugmaker. Most Read from Bloomberg Traders cited a report from the Yicai news service released earlier in the day, with the stock’s losses snowballing during afternoon trading. AstraZeneca…